Text Size

National Survey on GERD Patients (Adults and Children) (RGO à trav)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00833573
First received: January 30, 2009
Last updated: November 13, 2009
Last verified: November 2009
History of Changes
  Purpose

To describe GERD digestive expression according to ages: - children (from 0 to 23 months) and (24 months and more)- adults (from 18 to 29 years old), (from 30 to 39 years old), (from 40 to 49 years old), (from 50 to 59 years old), (more than 60 years old)


Condition
GERD (Gastroesophageal Reflux Disease)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: National Survey on GERD Patients (Adults and Children)

Resource links provided by NLM:

MedlinePlus related topics: GERD
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To describe GERD digestive expression according to ages: - children (from 0-23 months) and (24 months and more)- adults (from 18-29 years old), (from 30-39 years old), (from 40-49 years old), (from 50-59 years old), (more than 60 years old) [ Time Frame: once ] [ Designated as safety issue: No ]

Estimated Enrollment: 4400
Study Start Date: January 2009
Study Completion Date: October 2009
Groups/Cohorts
1
For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
2
For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.

Criteria

Inclusion Criteria:

  • Adults : - Male or female > or = 18 years old - With at least one GERD typical clinical sign (pyrosis and / or acid regurgitations).- Not receiving any GERD treatment within the 3 previous months.
  • Children :- Male or female < 18 years old - With GERD digestive clinical signs during the consultation (receiving treatment or not)- Whose parents or legal guardian gave oral approval to the child participation in the survey.

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00833573

  Show 1060 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00833573     History of Changes
Other Study ID Numbers: NIS-GFR-DUM-2008/2
Study First Received: January 30, 2009
Last Updated: November 13, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
GERD digestive expression
ages

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
 Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 18, 2013